Posters

Evaluation of in vitro glistening formation in different hydrophobic acrylic intraocular lenses

Poster Details

First Author: G. Auffarth GERMANY

Co Author(s):    R. Khoramnia   S. Liebing   P. Merz   E. Friedmann   T. Tandogan        

Abstract Details

Purpose:

To compare the glistening formation in different hydrophobic acrylic intraocular lenses (IOLs) of different manufacturers.

Setting:

The David J. Apple International Laboratory for Ocular Pathology, Dept. of Ophthalmology, University of Heidelberg, Germany

Methods:

Four hydrophobic IOL models (Avansee AU6KA [Kowa, Japan], enVista [Bausch&Lomb, USA], AcrySof MA60AC [Alcon, USA], Vivinex XY1 [Hoya, Japan]) were analyzed. Glistenings were created in an experimental setup as aqueous-filled microvacuoles in five IOLs per model using an accelerated laboratory method. The IOLs were immersed in water at 45°C for 24 hours and then placed in a water bath with a temperature of 37°C for 2.5 hours to reduce the temperature. Images of the IOLs were taken with a camera attached to a microscope. The images were analyzed with an image analysis software (i-Solution) for the comparison of glistening formation.

Results:

Glistenings were detectable in all lenses after the accelerated laboratory method. The range of the microvacuole density for the IOLs was as follows (in microvacuoles per square millimeter IOL surface [MVs/mm²]): 1-2 (enVista [Bausch&Lomb, USA]), 1-4 (Avansee AU6KA [Kowa, Japan]), 507-804 (AcrySof MA60AC [Alcon, USA]), 6-21 (Vivinex XY1 [Hoya, Japan]).

Conclusions:

The amount of glistenings differed significantly between the examined IOLs. While three IOL models (Avansee AU6KA, enVista and Vivinex XY1) only showed a glistening grade of 0 according to Miyata et al., the other model (AcrySof MA60AC) showed a glistening grade of 3.

Financial Disclosure:

One or more of the authors receives consulting fees, retainer, or contract payments from a competing company, One or more of the authors travel has been funded, fully or partially, by a competing company, One or more of the authors travel has been funded, fully or partially, by a company producing, developing or supplying the product or procedure presented, One or more of the authors research is funded, fully or partially, by a competing company, One or more of the authors research is funded, fully or partially, by a company producing, developing or supplying the product or procedure presented, One or more of the authors receives nonNONEmonetary benefits from a competing company., One or more of the authors receives nonNONEmonetary benefits from a company producing, developing or supplying the product or procedure presented.